Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Genomma Lab InternacionalB de CV's current 3-Year Share Buyback Ratio was -0.50%.
The historical rank and industry rank for Genomma Lab InternacionalB de CV's 3-Year Share Buyback Ratio or its related term are showing as below:
MEX:LABB'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -0.5 Med: 0.3 Max: 2.3
Current: -0.5
During the past 13 years, Genomma Lab InternacionalB de CV's highest 3-Year Share Buyback Ratio was 2.30%. The lowest was -0.50%. And the median was 0.30%.
MEX:LABB's 3-Year Share Buyback Ratio is ranked better than 64.34% of 645
companies
in the Drug Manufacturers industry
Industry Median: -1.9
vs MEX:LABB: -0.50
Genomma Lab InternacionalB de CV (MEX:LABB) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Genomma Lab InternacionalB de CV 3-Year Share Buyback Ratio Related Terms
MEX:LABB vs ZTS, UTHR, VTRS: 3-Year Share Buyback Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV 3-Year Share Buyback Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's 3-Year Share Buyback Ratio falls into.
Genomma Lab InternacionalB de CV 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -0.50 mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a 3-Year Share Buyback Ratio of -0.50 as of Mar. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Genomma Lab InternacionalB de CV and its competitors. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #230 out of 645 companies in the Drug Manufacturers industry, placing it in the top 35.7%.
Is Genomma Lab InternacionalB de CV's 3-Year Share Buyback Ratio too high?
Genomma Lab InternacionalB de CV's current 3-Year Share Buyback Ratio is -0.50. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #230 out of 645 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's 3-Year Share Buyback Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #230 out of 645 companies for 3-Year Share Buyback Ratio. This puts Genomma Lab InternacionalB de CV in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Genomma Lab InternacionalB de CV and its competitors. Genomma Lab InternacionalB de CV's current 3-Year Share Buyback Ratio is -0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.67, compared to a current price of MXN15.28 — trading 13.5% below its estimated fair value. The current 3-Year Share Buyback Ratio is -0.50. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current 3-Year Share Buyback Ratio is -0.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN15.28 is trading 13.5% below its estimated GF Value™ of MXN17.67.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
3-Year Share Buyback Ratio: -0.50
GF Value™: MXN17.67 vs. price of MXN15.28 (13.5% below fair value)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 